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Abstract
Background: SIRT is an emerging treatment for liver tumours which relies on the selective uptake
by tumour of 90Y microspheres following hepatic arterial injection. Response rates of around 90%
are reported. Hepatic arterial injection of MAA gives an indication of the expected distribution of
90Y microspheres within the liver. This study sought to determine if the MAA scan could be
predictive of subsequent tumour response.
Methods: 58 patients with colorectal hepatic metastases received SIRT. All had pre-treatment
MAA planar images and CT scans which were retrospectively reviewed. Tumours were
qualitatively considered "cold", "equivocal" or "hot" based on MAA uptake and the ratio of uptake
in tumour and normal liver tissue was calculated (TNR). Following SIRT (which included the
administration of hepatic arterial Angiotensin 2) tumour response was assessed by CEA changes
one to two months after treatment and by serial CT.
Results: Uptake was classified as "hot" in 37 patients (Group 1) and "equivocal" or "cold" in 21
(Group 2). CEA levels fell dramatically in over 90% of patients. The falls were not significantly
different between the groups. There was no correlation between TNR and tumour response based
on CEA changes (r2 = 0.004). CT responses after 3 months were not different in the 2 Groups.
Conclusion: The pattern of MAA uptake by colorectal liver tumours after arterial injection is not
a predictor of tumour response after treatment by SIRT. The results suggest the doses of 90Y
microspheres used may be greater than is necessary.
Background
Colorectal cancer (CRC) is a particularly common cancer
encountered worldwide. Although the primary site is
resectable in the majority of instances, metastatic disease
will be present or develop in some 50% of those affected
within 5 years of presentation. As a result of the portal
venous route of spread, the liver is the commonest site of
metastases and is frequently the only evident site [1]. This
feature of CRC, coupled with the disappointing results
achieved with systemic chemotherapy, has lead to interest
in the development of effective regional liver therapies.
Such regional approaches include liver resection, cryo-
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therapy or radiofrequency ablation, regional chemother-
apy and selective internal radiation therapy (SIRT).
SIRT has been shown to be a particularly effective form of
local treatment of CRC liver metastases even when large
volumes of tumour are present in multiple sites [2,3]. It
involves selective delivery to tumours of a high dose of
ionising radiation achieved by injecting 90Yttrium micro-
spheres directly into the hepatic artery. The microspheres,
because of their size (25–35 µm) become trapped in cap-
illary beds and preferential uptake into tumour tissue is
achieved because of the predominant arterial blood flow
to liver tumours relative to normal liver parenchyma [4].
Radiation dosing is therefore non-homogeneous and the
precise dose received will vary within tumour and normal
liver tissue and from patient to patient. However average
doses received by tumour and normal liver tissue have
been calculated to be 200–300Gy and 15–25Gy respec-
tively [5]. A supra-lethal dose of radiation is therefore
received by much of and occasionally all of the tumour,
while the dose received by the normal liver tissue is insuf-
ficient to result in clinically relevant radiation hepatitis.
We and others have shown that fewer than 10% of
patients with CRC liver metastases will not respond to this
form of treatment based on serial CT scanning and
tumour marker (CEA) data [2,3]. While definitive evi-
dence of extended survival is not yet available, all data
point strongly to some survival advantage, at least for
those who do not develop extrahepatic disease at an early
stage [2,6]. Selection of those patients most suitable for
this form of treatment might be aided by development of
a test capable of predicting liver tumour response after
SIRT.
99mTc-MAA scans are routinely advised and performed
prior to SIRT to confirm access to all areas of the liver from
the hepatic artery and isolation of the liver from other
foregut structures [7]. 99mTc-MAA has a "particle" size
(10–60 µm, average 35 µm) similar to the resin micro-
spheres used for SIRT and can therefore be used as a tracer
dose to indicate approximate distribution of 90Yttrium
microspheres to be expected during SIRT. Tumours with
high 99mTc-MAA uptake can be expected to receive a high
dose of 90Yttrium microspheres and it seems possible they
may respond correspondingly better than tumours dem-
onstrating low uptake of 99mTc-MAA. This hypothesis has
not previously been thoroughly tested. There have how-
ever been contradictory reports regarding the association
between  99mTc-MAA uptake by hepatic tumours and
response after hepatic artery chemotherapy (HAC) [8-11].
The purpose of this study was to determine whether the
pattern of uptake of 99mTc-MAA after arterial injection, by
colorectal liver metastases is predictive of tumour
response after SIRT.
Methods
Between February 1997 and February 2000, 61 patients
with extensive colorectal liver metastases, not suitable for
either resection or cryotherapy, were treated with SIRT. All
patients being so treated gave written informed consent
for their treatment, as required and approved by the Wel-
lington Regional Ethics Committee. Patients were
assessed prior to treatment with CT scans of the chest (or
chest Xray), abdomen (and pelvis if appropriate), and
standard blood tests including liver function tests (LFTs)
and carcinoembryonic antigen (CEA). While CT scans of
the chest and bone scans were not routinely performed
they were done in many patients. Patients with anything
more than minor extrahepatic metastatic disease were
excluded from this treatment.
Laparotomy was performed for placement of an hepatic
artery Porta-cath®  via the gastroduodenal artery in 54
patients, by a previously described technique which
entailed ligation of anomalous (duplicated/triplicated)
hepatic arteries and small vessels passing to non-hepatic
structures [2]. These patients subsequently received a sin-
gle dose of SIR-spheres® (Sirtex Medical Pty Ltd, Sydney)
via this catheter, which was followed by 4-weekly cycles of
continuous 5-fluorouracil (5FU) at a dose of 1 g per day
for 4 days each cycle. In the remaining 7 patients a hepatic
artery catheter (3F Tracker) was placed into the hepatic
artery via the femoral artery using a Seldinger technique
for the purpose of SIRT. The gastroduodenal artery was
embolised unless the catheter could be advanced beyond
this artery and still provide access to both left and right
hepatic arteries. These patients received a single dose SIR-
spheres® via the catheter but did not receive subsequent
regional or other chemotherapy. The dose of SIR-spheres®
administered was modified according to an estimate of
liver tumour volume, based on viewing of the pre-opera-
tive CT scan. Thus:
less than 25% liver involvement: 2.0GBq
25–50% liver involvement: 2.5GBq
greater than 50% liver involvement: 3.0GBq
One to two hours prior to SIRT, a 99mTc-MAA liver scan
(MAA scan) was undertaken as follows. 100–120 MBq
(2.7–3.2mCi) of 99mTc-MAA (Amersham Pulmonate II
from UK, particle size 10–60 µm, average 35 µm) in 0.23–
0.27 ml was administered into the hepatic artery either via
the Port or the percutaneous arterial catheter at a rate of
approximately 1 ml/10 sec followed by a flush with 10 ml
of normal saline then 5 ml of heparinised saline. Immedi-
ately following this injection, images were obtained on a
GE Starcam gamma camera. Anterior views of the chest
and abdomen and lateral views of the abdomen wereBMC Nuclear Medicine 2005, 5:7 http://www.biomedcentral.com/1471-2385/5/7
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acquired for 2 minutes per view on a 256 × 256 matrix
with the patient in a supine position. The primary purpose
of this scan was to enhance the safety of the subsequent
administration of SIR-spheres®, by demonstrating the
absence of obvious access to extrahepatic sites within the
abdomen and by permitting calculation of the degree of
liver-lung shunting. It has been shown that if the liver-
lung shunt exceeds 13%, there is appreciable risk of radi-
ation pneumonitis and in that event the procedure should
be abandoned, or the dose of SIR-spheres® reduced [12].
A few minutes prior to delivery of SIR-spheres®, 50 µg
Angiotensin II (Hypertensin, Novartis) was injected into
the hepatic artery to achieve vasoconstriction of the arteri-
oles to normal liver tissue thereby aiding selective uptake
of the microspheres by tumour within the liver. SIRT was
administered under light sedation with Hypnovel®
(Roche) and intravenous narcotic analgesia by injecting
SIR-spheres®, into the hepatic artery at a rate of approxi-
mately 1 ml/10 sec over some 10 minutes. The technique
has been described in more detail elsewhere [2,13].
Blood tests, including albumin, bilirubin, alkaline phos-
phatase (ALP), alanine transaminase (ALT), and aspartate
transaminase (AST) were performed prior to and at 24
and 48 hours following SIRT in the majority of patients.
Patients were seen at monthly intervals for review, at
which time blood tests including CEA were done. Repeat
CT scans were performed at 3-monthly intervals during
follow-up. The higher of the values of ALT and AST at 24
or 48 hrs after SIRT was used as an indicator of the degree
of injury to normal liver parenchyma. All serum concen-
trations of CEA and LFTs have been expressed as mean ±
sd (confidence interval).
Assessment of MAA scans
(a) Qualitative assessment
This was independently undertaken by two investigators
(AD and RSS). Two sketches of the liver were made for
each patient by each investigator. On the first was marked
the sites of metastatic disease within the liver after viewing
the pre-operative CT scan and/or operation note. On the
second was marked the sites of most intense uptake of
99mTc-MAA as shown by the MAA scan. The second sketch
(MAA uptake) was completed without viewing the first
(site of deposits). Each investigator then compared their
two sketches for each patient and assessed the liver
tumour sites to be "hot", "equivocal" or "cold" as follows:
"hot": greater uptake of 99mTc-MAA by the tumour than
the unaffected liver
"equivocal": similar uptake of 99mTc-MAA by the tumour
and the unaffected liver
"cold": less uptake of 99mTc-MAA by the tumour than the
unaffected liver
In the event of a different assessment being made by the
two investigators, as occurred in 13 patients, a joint reas-
sessment was undertaken and a consensus reached. This
was not usually difficult. For the purpose of statistical
Example showing scans of a patient with MAA uptake described as "hot" Figure 1
Example showing scans of a patient with MAA uptake described as "hot".
TNR = 2.6BMC Nuclear Medicine 2005, 5:7 http://www.biomedcentral.com/1471-2385/5/7
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analysis those patients with a "hot" pattern of uptake were
termed Group 1 and those with "equivocal" or "cold"
uptake were termed Group 2.
(b) Quantitative assessment
This was conducted by a third investigator (PL) and
entailed a quantitative assessment of the ratio of 99mTc-
MAA uptake by tumour and normal liver (TNR). Once
again a sketch was made showing the sites of tumour
within the liver. The stored computerised images of the
MAA scans for each patient were reviewed and a total of 4
to 6 circular regions of interest were drawn on each scan
corresponding to sites of tumour and a further 4 to 6
regions of interest corresponding to unaffected normal
liver. The diameter of each region of interest was the same
for each patient, but varied somewhat between patients
(1.0 – 2.6 cm). The TNR for each patient was calculated by
dividing the average count for the areas of tumour by the
average count for the areas of non-affected liver.
Assessment of tumour response to SIRT
This was assessed by changes in both CEA and by CT scan-
ning following SIRT. Percentage reduction in CEA was cal-
culated for each patient from the pre-operative level to the
lower of the levels at 1 or 2 months following SIRT. This
time point was chosen so as to most accurately reflect the
response to the SIRT while minimising any effect of ongo-
ing hepatic artery chemotherapy and any effect of subse-
quent disease progression in the liver or extrahepatic sites.
CT changes within the liver were defined as follows:
tumour regression: definite reduction in size of index
lesions
stable disease: no definite increase or decrease in lesion
size
progressive disease: definite increase in size of index
lesions
Survival
Patient survival was assessed both from time of diagnosis
and time of treatment.
Statistical analysis
Differences in tumour and patient characteristics between
groups before and after SIRT were analysed using a paired
or unpaired Students t-test or chi-square test as appropri-
ate. Because the CEA data was not normally distributed,
all CEA values were log-transformed prior to statistical
analysis. The chi-square test was used to assess the signifi-
cance of differences in response rates judged by serial CT
scanning. Estimated survival of patients was calculated by
the Kaplan-Meier method and statistical analysis per-
formed using the logrank test. A p value of less than 0.05
was considered significant in all analyses. Linear regres-
Example showing scans of a patient with MAA uptake described as "equivocal" Figure 2
Example showing scans of a patient with MAA uptake described as "equivocal".
TNR = 0.2BMC Nuclear Medicine 2005, 5:7 http://www.biomedcentral.com/1471-2385/5/7
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Example showing scans of a patient with MAA uptake described as "cold" Figure 3
Example showing scans of a patient with MAA uptake described as "cold".
TNR = 0.4
Table 1: Patient demographics and tumour pathology.
Group 1 Group 2
hot (n = 37) equivocal (n = 12) cold (n = 9)
Age years median (range) 61 (33–76) 56 (40 – 72) 64 (50 – 75)
Gender
Female 21 1 3
Male 16 11 6
ACPS* staging of colonic primary
A3 1 0 0
B1 & B2 6 1 4
C1 & C2 29 10 4
Unknown 1 1 1
Histology of colonic primary
well differentiated 1 2 0
moderately differentiated 28 4 6
poorly differentiated 7 2 2
unknown 1 4 1
Liver tumour diagnosis
synchronous 27 6 5
metachronous 10 6 4
Estimated liver involvement
<25% 19 5 6
25–50% 8 5 1
>50% 10 2 2
Dose of 90Yttrium given
2.0 GBq 21 6 7
2.5 GBq 10 4 2
3.0 GBq 6 2 0
Liver / lung shunt, median (range) 0.3% (0 – 9.3%) 0.2% (<0.1 – 3%) 0.2% (0.1 – 1.5%)
HAC given after SIRT 34 10 8
* Australian clinico-pathogical stagingBMC Nuclear Medicine 2005, 5:7 http://www.biomedcentral.com/1471-2385/5/7
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sion was used to seek any correlation between the tumour
response rate (judged by changes in CEA) and TNR uptake
of 99mTc-MAA prior to SIRT and the coefficient of determi-
nation (r2) was calculated.
Results
Of the 61 patients who received SIRT for colorectal liver
metastases, three patients were excluded from this study
because pre-treatment CT scans were not available for
comparison with the pre-SIRT MAA scan. Thus the study
group included 58 patients (38 males and 20 females),
with a median age at treatment of 61 years (range 33–76).
The median time from diagnosis of colorectal liver metas-
tases to treatment with SIRT was 2.8 months (range 0.5 –
71.6).
99mTc-MAA uptake by CRC hepatic metastases
The pattern of uptake of 99mTc-MAA by the liver was "hot"
in 37 patients (Group 1). In the remaining 21 patients
(Group 2), the pattern was "equivocal" in 12, and "cold"
in 9 patients. Examples of these various patterns of uptake
are given in Figures 1, 2, 3.
Patient demographics, tumour characteristics and details
concerning treatment given are shown in Table 1. There
was no significant difference in any of these features
between patients from Groups 1 and 2. Pre-treatment liver
function tests are shown in Table 2. There was no signifi-
cant difference in the levels of bilirubin, ALP, ALT, or AST
between the two groups, however albumin levels were sig-
nificantly lower in Group 1 patients than those of Group
2 (p = 0.01). Changes in ALT and AST levels in the 48 hour
period following SIRT are shown in Table 3. This data was
not available for 8 patients. A significant rise in AST but
not ALT was noted in patients from both Group 1 (p =
0.03) and Group 2 (p = 0.05) following SIRT. There was
however no significant difference between the rises of
either AST or ALT between the two groups.
Relationship between 99mTc-MAA uptake and tumour 
response
Tumour response assessed by CEA changes
Four patients did not have CEA levels measured after SIRT
because of their deteriorating condition. Details of CEA
levels in Group 1 and 2 patients are shown in Table 4.
Thirty four patients from Group 1 had elevated CEA levels
prior to SIRT and 3 patients had normal levels. Following
SIRT, 29 of these showed a fall in CEA by 2 months, 3
showed a rise, 2 continued to maintain normal levels and
in 3 the CEA changes were not assessed. Twenty patients
from Group 2 had elevated CEA levels prior to SIRT and 1
patient had a normal CEA level. Following SIRT, 18 of
Table 2: Serum liver function tests before SIRT [mean ± sd (confidence interval)].
Group 1 Group 2
"hot" "equivocal" "cold"
number of patients 37 12 9
albumin g/L 36 ± 6 (34 – 38)* 38 ± 4 (34 – 41) 41 ± 4 (38 – 44)
bilirubin umol/L 16 ± 12 (12 – 20) 16 ± 17 (6 – 26) 11 ± 7 (6 – 16)
ALP iu/L 309 ± 335 (201 – 417) 272 ± 149 (188 – 356) 194 ± 139 (-12357 – 12745)
ALT iu/L 92 ± 122 (53 – 131) 60 ± 53 (30 – 90) 51 ± 35 (28 – 74)
AST iu/L 83 ± 149 (35 – 131) 59 ± 44 (34 – 84) 43 ± 34 (21 – 65)
* p = 0.01 between Groups 1 and 2
Table 3: Serum transaminase levels before and after SIRT (paired data) [mean ± sd (confidence interval)]. AST levels rose significantly 
after SIRT in both Groups but there was no significant rise in ALT following SIRT in either Group. There was no significant difference 
in the rise of ALT or AST after SIRT between the two Groups.
Group 1 Group 2
"hot" "equivocal" "cold"
number of patients 31/37 12/12 7/9
ALT iu/L
pre-SIRT 97 ± 128 (52 – 142) 60 ± 53 (30 – 90) 56 ± 36 (30 – 83)
post-SIRT 146 ± 121 (103 – 188) 263 ± 316 (84 – 442) 1665 ± 2517 (-199 – 3530)
AST iu/L
pre-SIRT 88 ± 162 (31 – 145) 59 ± 44 (34 – 84) 48 ± 37 (20 – 75)
post-SIRT 200 ± 205 (128 – 272) 379 ± 437 (131 – 626) 1657 ± 2562 (-241 – 3555)BMC Nuclear Medicine 2005, 5:7 http://www.biomedcentral.com/1471-2385/5/7
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these showed a fall in CEA by 2 months, 1 showed a rise,
1 continued to maintain normal levels and in 1 the CEA
level was not assessed. A significant fall in CEA was
observed in both Group 1 and 2 patients over the 2
months following SIRT (p <0.001) indicating tumour
responses in both groups. There was no significant differ-
ence between the pre-SIRT CEA level (p = 0.06) or the low-
est CEA level 1 or 2 months after SIRT (p = 0.06), between
the two groups.
Tumour response assessed by CT changes
Seven patients did not have a follow-up CT scan after SIRT
because of their deteriorating condition. Tumour
responses judged by CT scan 3 months after SIRT are
shown in Table 5. Some tumour regression was seen in the
majority of patients from both groups with tumour pro-
gression being seen in only 3/51 (6%) patients. There was
no significant difference between the proportion of CT
responses observed in the 2 groups.
Quantitative assessment of TNR showed a mean of 0.5 for
the "cold" lesions, 1.0 for the "equivocal" lesions and 2.4
for the "hot" lesions. The mean ± sd TNR for all patients
was 1.83 ± 1.56. For Group 1 it was 2.4 ± 1.6 and for
Group 2 it was 0.8 ± 0.5. These differences were statisti-
cally significant (p = 0.0002). There was however no sig-
nificant correlation between the TNR and the tumour
response as judged by the percentage change in CEA 1 to
2 months after SIRT (see Figure 4). The coefficient of
determination for this relationship was 0.004.
Survival after liver tumour diagnosis and SIRT
Median follow-up for all patients after SIRT is 11.6
months (range 1 – 50.2). Median survival from diagnosis
of liver metastases for all patients is 14.1 months (range
1.9 – 91.4) and from treatment is 11 months (range 1.0 –
50.2). Kaplan-Meier cumulative proportion surviving ± se
after SIRT is 75.8% ± 6 at 6 months, 50.0% ± 7 at 12
months, 34.5% ± 6 at 18 months, 20.1% ± 6 at 24
months, and 12.1% ± 4 at 30 months.
A comparison of the estimated survival following treat-
ment for Groups 1 and 2 patients is shown in Figure 5. For
Group 1 the median survival from diagnosis of liver
metastases is 16 months (range 1.9 – 91.4). Median sur-
vival time from treatment is 11 months (range 1.0 – 48.5)
and the cumulative proportion surviving ± se at 6 months
is 78.4% ± 7, 48.6% ± 8 at 12 months, 35.1% ± 8 at 18
months, and 18.9 % ± 6 at 24 months. For Group 2 the
median survival from diagnosis of liver metastases is 14.1
months (range 5.4 – 75.8). Median survival time from
treatment is 12.3 months (1.9 – 50.2) and the cumulative
proportion surviving ± se at 6 months is 71.4% ± 10,
50.0% ± 11 at 12 months, 31.8% ± 10 at 18 months, and
22.7% ± 9 at 24 months. The difference in survival for
Table 4: Serum CEA levels before SIRT and the lowest level either 1 or 2 months after SIRT. A significant fall in CEA was seen in both 
groups after SIRT. The difference between the fall after SIRT in the two groups was not statistically significant.
Group 1 Group 2
"hot" "equivocal" "cold"
CEA (ng/ml) pre-SIRT
number of patients 37 12 9
mean ± sd (C.I.) 2071 ± 5598 (267 – 3874) 433 ± 628 (77 – 789) 247 ± 390 (-8 – 502)
median (range) 235 (1.1 – 25620) 113 (1.8 – 1749) 41 (4.3 – 1150)
CEA (ng/ml) post-SIRT
number of patients 34/37 12/12 8/9
mean ± sd (C.I.) 428 ± 983 (97 – 758) 50 ± 55 (19 – 81) 41 ± 75 (-14 – 97)
median (range) 15 (1.2 – 4590) 42 (1.9 – 170) 6 (0.8 – 216)
Table 5: Tumour response assessed by CT changes 3 months after SIRT. There was no significant difference between the proportion of 
responses seen in the two groups.
Group 1 Group 2
"hot" "equivocal" "cold"
number of patients 33 10 8
tumour regression 24 8 6
stable disease 7 2 1
progressive disease 2 0 1BMC Nuclear Medicine 2005, 5:7 http://www.biomedcentral.com/1471-2385/5/7
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patients in Group 1 and Group 2 is not statistically signif-
icant.
Discussion
Selective Internal Radiation Therapy is an emerging
regional approach to the treatment of liver cancer. Unlike
other regional ablative techniques such as cryotherapy,
radiofrequency ablation, and laser ablation SIRT is appro-
priate and efficacious for both small volume and large vol-
ume non-resectable disease. Reported response rates are
around 90% and in most instances substantial tumour
destruction is achieved. Tumour marker data suggests a
median destruction of 85–90% of liver tumour by a single
treatment with SIRT [2,3]. The cancers with which most
experience has been obtained to date are colorectal liver
metastases and primary hepatocellular cancer. In the case
of the former, the only other local treatment suitable for
patients irrespective of the extent of liver involvement is
regional chemotherapy. While there is considerable data
supporting the use of regional chemotherapy, results are
not as reliable or as impressive as with SIRT. The one ran-
domised trial which has been performed comparing
regional chemotherapy with SIRT plus regional chemo-
therapy in patients with advanced CRC liver metastases
showed benefit from the addition of SIRT both in terms of
response rates and survival [6].
To date experience with SIRT has been confined to a rela-
tively small number of centres with published reports of
treatment in over 20 patients coming from very few
groups [2,3,5,14-16]. Experience however, is accumulat-
ing and has been reported with two types of 90Yttrium
microspheres – a resin based microsphere (SIR-spheres®)
[2,3,5] and a glass microsphere (Therasphere®) [14-16].
While excellent response rates have been reported for
both, more detailed information regarding treatment and
outcomes with resin microspheres is currently available.
However, much more work needs to be done to refine
selection of patients, and treatment schedules.
MAA scans are currently performed as a routine prior to
SIRT for the purpose of confirming access to the liver by
the delivery system, excluding access to extrahepatic
foregut sites, and defining the extent of any liver/lung
shunt. This is important for minimising the risk of poten-
tially fatal adverse effects such as radiation pneumonitis
or radiation gastritis/duodenitis [12,17]. As MAA particles
are of similar size to SIR-spheres®  it is reasonable to
assume the two will be distributed similarly within the
liver. The present study set out to determine whether the
pattern or degree of MAA uptake by liver tumours after
hepatic arterial injection might be a predictor of response
to subsequent SIRT with SIR-spheres®. It seemed likely the
results of such a study would have potentially important
implications regarding selection of patients for SIRT or the
determination of an appropriate dosing schedule. At the
time this study was undertaken SPECT imaging was not
available to us, as indeed it is still not for many of the cen-
tres undertaking SIRT. The use of simple planar images for
the quantitative element of this study brings a degree of
approximation to the measurement of the MAA uptake,
which must be acknowledged, but which the authors
believe does not alter the underlying message of the study.
This belief is based on knowledge and experience gained
by the authors over the last two years during which time
SPECT/CT imaging of MAA studies has been available to
us.
There is an important difference in the blood supply of
liver tumours and normal liver parenchyma which is
exploited by regional hepatic arterial delivery of antican-
cer agents such as chemotherapy or 90Yttrium micro-
spheres. Malignant liver tumours derive some 95% of
their blood supply from the hepatic artery, whereas only
25–30% of the blood supply of normal parenchyma is
from the hepatic artery [4]. The balance comes from the
portal vein. MAA perfusion scans should give a reasonably
reliable indication of the relative arterial flow to liver
tumour and normal liver parenchyma. Theoretically, a
higher degree of vascularity within the tumour will result
in greater arterial blood flow (relative to normal liver
parenchyma) and therefore greater receipt of any thera-
peutic agent delivered via the hepatic artery. The present
study reveals considerable variation in the arterial blood
flow to CRC liver metastases relative to normal liver with
TNR ranging from a low of 0.1 to a high of 9.7 with a
mean of 1.83. The majority (37/58 or 64%) of CRC liver
metastases do have greater arterial blood flow than nor-
Linear regression line showing no correlation between TNR  uptake of MAA and tumour response as assessed by the CEA  change after one or two months (whichever is the greater)  after SIRT Figure 4
Linear regression line showing no correlation between TNR 
uptake of MAA and tumour response as assessed by the CEA 
change after one or two months (whichever is the greater) 
after SIRT.
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mal liver and therefore appear "hot" on an MAA perfusion
scan. Patient characteristics and tumour stage, grade and
extent do not appear to influence tumour vascularity as
judged by TNR.
Early studies of internal radiation therapy reported that
patients with relatively avascular tumours, as demon-
strated by arteriography, did not respond as well as those
patients with moderately to highly vascular tumours
[18,19]. These studies, however, involved relatively small
numbers and included patients with a variety of different
primary cancers. Furthermore arteriography may not be a
particularly accurate way of assessing tumour blood flow.
The relationship between vascularity of CRC hepatic
tumours and response to HAC has been studied by a
number of groups. An early study by Kim et al observed
that the more vascular the hepatic tumour on angiogram,
the better the prognosis following hepatic artery ligation
and infusional chemotherapy [20]. Subsequently, a
number of authors [8-10] described a correlation between
perfusion of CRC liver metastases, measured by 99mTc-
MAA scans, and response to HAC. They concluded that
increased tumour perfusion allows for a higher response
rate from this particular treatment modality. Lehner et al
on the other hand, found no correlation between tumour
vascularity, as indicated by 99mTc-MAA scan, and response
or survival following HAC in a study involving 36 patients
with CRC liver metastases. They suggested that the degree
of neo-vascularisation may only be demonstrated by
super-selective catheterisation and questioned whether
perfusion studies by angiogram or 99mTc-MAA reliably
reproduce the perfusion pattern produced by the much
slower flow rate used for chemotherapy [11]. In a rela-
tively recent publication Dancey et al reported a better
response of non-resectable HCC to SIRT with Theras-
pheres® for patients with "hot" lesions on MAA scan, than
those with "cold" lesions [15].
The present study relates to SIRT in CRC metastases and
has adopted a more methodical approach to assessing the
question than that taken in Dancey's report of SIRT in
HCC, and includes a larger number of patients. Not only
have we attempted to quantify the MAA uptake more pre-
cisely, but we have also attempted to quantify the tumour
response more precisely using changes in tumour marker
after SIRT. The findings are clear. With the doses used
there is no correlation between MAA uptake into CRC
liver metastases prior to SIRT (TNR) and response to the
treatment in terms of tumour marker data, CT data or sur-
vival time. Intuitively, one might have expected the oppo-
site finding. The most obvious implication of this is that
the doses of SIR-spheres®  being administered may be
higher than is required for obtaining a response in most
patients. This possibility should be investigated. Compar-
ison between the findings of our and Dancey's study sug-
gests a higher dose of 90Y microspheres is required for
therapeutic effect in HCC than CRC. The fact that the SIR-
spheres® were administered to the patients after giving
angiotensin 2 into the hepatic artery, whereas the MAA
perfusion scans were performed without angiotensin 2,
potentially confounds the results and is unfortunately a
weakness arising out of the retrospective nature of the
study. The vasoconstriction achieved by angiotensin 2 has
been shown to assist selective tumour uptake [21] and
provides the theoretical basis for its use. Most units deliv-
ering SIRT do not use angiotensin 2 as it is no longer read-
ily available and this does not obviously compromise
results. The authors feel it is unlikely that the lack of cor-
relation between TNR uptake of MAA and tumour
response to SIRT would be accounted for by the adminis-
tration of angiotensin 2, but it remains a possibility. If a
positive correlation between the pattern of MAA uptake
and tumour response was subsequently shown by another
group, not using angiotensin 2, an argument might be
raised supporting the routine use of a vasoconstrictor dur-
ing SIRT. We currently use a bolus dose of phenylephrine
hydrochloride 100 µg in lieu of angiotensin 2, on the
grounds this may be of value, and no harm is conferred.
We have observed and previously reported that patients
receiving SIRT using the dosing schedule of the present
study suffer profound lethargy and anorexia for up to 4–6
weeks after the treatment [2]. The present study provides
data to indicate that damage is sustained by normal hepa-
tocytes, as indicated by a significant transaminase rise,
after SIRT. There is however, no indication that the extent
Kaplan-Meier survival curves for Group 1 patients ("hot"  lesions) and Group 2 patients ("equivocal" or "cold" lesions) Figure 5
Kaplan-Meier survival curves for Group 1 patients ("hot" 
lesions) and Group 2 patients ("equivocal" or "cold" lesions). 
There is no statistical difference in cumulative survival by 
logrank test.
Survival Time (months)
C
u
m
u
l
a
t
i
v
e
P
r
o
p
o
r
t
i
o
n
S
u
r
v
i
v
i
n
g
0 1 22 43 64 86 07 2
0.00
0.25
0.50
0.75
1.00
Group 1
Group 2BMC Nuclear Medicine 2005, 5:7 http://www.biomedcentral.com/1471-2385/5/7
Page 10 of 10
(page number not for citation purposes)
of this damage relates to the TNR of MAA uptake. Again
this suggests that the doses being given are sufficiently
great to result in liver damage occurring in a non dose-
dependent fashion. If the adverse effects of anorexia and
lethargy relate to the damage of normal liver tissue, as
seems possible, then a smaller dose of SIR-spheres® might
be better tolerated without compromising anti-tumour-
efficacy. It follows that a dosing schedule employing
repeated smaller doses of SIR-spheres® might be better tol-
erated than present schedules while achieving mainte-
nance of a high response rate. Again this possibility is
worthy of investigation.
Conclusion
The present study confirms the high rate of response of
CRC liver metastases to SIRT reported previously by our
group and others. However, it finds no relationship
between the pattern of MAA uptake by metastatic colorec-
tal liver tumours and response obtained, at least for the
doses of SIR-spheres® administrated in this study.
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